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Introduction
Lipid lowering may improve exercise performance in
peripheral arterial disease (PAD), but it is unknown how
it affects local vessel wall atherosclerosis as measured by
CMR.
Purpose
We hypothesized that lowering LDL cholesterol in PAD
would reduce superficial femoral artery (SFA) plaque bur-
den assessed by magnetic resonance imaging.
Methods
Thirty eight patients with mild-to-moderate symptomatic
PAD (mean age 64 ± 10 years, ankle brachial index 0.70 ±
0.13) were followed for two years on lipid lowering ther-
apy. Statin-naïve patients were randomized to simvastatin
40 mg or simvastatin 40 mg plus ezetimibe 10 mg (R
group, n = 20). Those already on a statin were given open-
label ezetimibe 10 mg (Z group, n = 18). Patients had the
first 15-20 cm of the SFA in their most symptomatic leg
imaged with black blood multi-slice turbo spin echo CMR
annually (Figure 1). Plaque volume (PV) defined as total
vessel volume (TVV) minus lumen volume was measured.
Changes in parameters within the R and Z groups over the
two years were analyzed with one way ANOVA and
between group changes were compared with an unpaired
t-test.
Results
R group designation remains blinded until 2-year follow-
up is finished. LDL at baseline in R was 119 ± 43 mg/dl
and fell significantly at one year (81 ± 38, p < 0.001) and
remained decreased at two years (83 ± 45). The LDL in Z
at baseline was 98 ± 27 mg/dl, decreased significantly at
one year (74 ± 35, p = 0.005), and was similar at year 2
(76 ± 27). Total cholesterol changes were similar in both
groups. The baseline LDL and total cholesterol in R were
greater than Z (p = 0.04 and p = 0.05 respectively), how-
ever the year 1 and 2 values were similar between groups.
See Table 1 for absolute changes in plaque volume and
TVV over time. When expressed as % change over 2 years
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Representative image of SFA (arrow) of R patient with less plaque at year 2Figure 1
Representative image of SFA (arrow) of R patient 
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relative to baseline, there was a trend towards plaque
regression in R relative to Z at 2 years (-4.5 ± 13.2% vs.
+2.6 ± 8.8%, p < 0.07). TVV regressed in R compared to Z
over the same time period (-3.3 ± 8.9% vs. +5.9 ± 9.1%, p
< 0.001).
Conclusion
Treating statin-naïve patients with PAD with a statin for
two years halted progression of SFA atherosclerosis rela-
tive to those already treated with statin begun on
ezetimibe, as assessed by CMR. This occurred despite sim-
ilar final LDL. The mechanism or timing of statin initia-
tion may be more important than the absolute LDL
achieved in slowing progression of atherosclerotic plaque
in the SFA.
Table 1: Changes in Vessel Wall Characteristics
Baseline One Year Two Years ANOVA p
R - Plaque volume (cm3) 11.1 ± 4.7 11.0 ± 5.3 10.5 ± 4.4 0.09
Z - Plaque volume (cm3) 9.6 ± 4.0 10.2 ± 5.1 9.8 ± 4.2 0.21
R - TVV (cm3) 16.4 ± 7.0 16.1 ± 7.3 15.8 ± 6.8 0.22
Z - TVV (cm3) 13.4 ± 6.1 15.9 ± 6.9 16.2 ± 6.3* 0.04
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